

PRESS RELEASE

Gradientech Secures Significant U.S. Distributor Order from Hardy Diagnostics

Uppsala, Sweden, July 10, 2025. The diagnostics company Gradientech today announces a significant order from its North American distributor, Hardy Diagnostics, marking an important milestone in Gradientech's U.S. market expansion strategy.

As part of early market access and in parallel with ongoing clinical studies in the U.S., the QuickMIC® system - designed for ultra-rapid antibiotic susceptibility testing (AST) - is now available for Investigational Use Only (IUO) in the U.S. market. The first major commercial order from Hardy Diagnostics represents a strong vote of confidence in Gradientech's technology, offer, and capabilities, while also highlighting the growing interest in the QuickMIC system across the U.S.

"At Hardy Diagnostics, we are committed to bringing the most advanced and impactful technologies to our customers. Gradientech's QuickMIC system represents a significant leap forward in rapid antimicrobial susceptibility testing, and we are excited to introduce it to the U.S. market, currently under IUO status," says Mark Carpenter, Director of Sales and Marketing, Hardy Diagnostics. "This first major purchase marks the beginning of what we believe will be a transformative partnership in the fight against antimicrobial resistance."

"This order is a testament to the strength of our QuickMIC system and the growing trust we've built with our partner, Hardy Diagnostics," says Sara Thorslund, CEO and co-founder of Gradientech. "It's a pivotal step in our long-term strategy to establish a strong footprint and making our QuickMIC system accessible to customers across the North American market."

QuickMIC® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a breakthrough device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.